Bioxytran (BIXT) Return on Assets (2011 - 2026)

Bioxytran (BIXT) posted Return on Assets of 0.04% for Q1 2026, up 14.48% sequentially from 0.05% in Q4 2025, and up 19.0% YoY from 0.04% in Q1 2025.

Bioxytran (BIXT) Return on Assets (2011 - 2026) Analysis & Trends

Bioxytran has reported Return on Assets for 16 years, with the latest figure at 0.04% in Q1 2026.

Quarterly Return on Assets rose 19.0% year-over-year to 0.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04% (up 19.0% YoY) and the FY2025 annual result came in at 0.05%, up 12.0% from the prior year.
Return on Assets rose to 0.04% in Q1 2026 per BIXT's latest filing, from 0.05% in the prior quarter.
Over five years, Return on Assets peaked at 0.04% in Q1 2026 and troughed at 0.33% in Q1 2024.
A 5-year average of 0.16% and a median of 0.16% in 2024 frame the typical range for Return on Assets.
The sharpest annual moves came in 2024 and 2026: Return on Assets fell 24 bps in 2024, then gained 19 bps in 2026.
Over 5 years, Return on Assets stood at 0.07% in 2022, then tumbled by 327 bps to 0.28% in 2023, then surged by 42 bps to 0.16% in 2024, then jumped by 67 bps to 0.05% in 2025, then increased by 14 bps to 0.04% in 2026.
According to Business Quant data, Return on Assets over the past three periods registered 0.04%, 0.05%, and 0.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.00%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Bioxytran	2.52 Mn	2.27 Mn	-	-0.07%

Download Data